PROGRAM
Toward Elimination of Viral Hepatitis:
Achievements, Challenges, and Prospects
September 21-23, 2023 ㅣ BEXCO, Busan, Korea
08:30-09:50
Pre-Congress Symposium
Updates on Epidemiology and the Natural Course of Viral Hepatitis in the Asian-Pacific Region (HBV)
Updates on Epidemiology and Natural Course of Viral Hepatitis in the Asian-Pacific Region (HCV)
Clinical Impacts of Epidemiological Growth of Nonalcoholic Fatty Liver Disease in the Asian-Pacific Region
Cure of Viral Hepatitis: Definition and Sub-Classification
Overview of Barriers to Hepatitis B Virus Cure
Overview of Barriers to Hepatitis C Virus Cure
Opening Ceremony
10:20-10:50
Presidential Lecture
How to Encourage and Organize Young Members of a Liver Society
10:50-11:50
Symposium 1-1. Hepatitis Elimination by 2030: Where Are We Now?
Hepatitis B Virus 2023: New Therapeutic Strategies against an Old Foe
Hepatitis C Virus 2023: The Road to Elimination of the Hepatitis C Virus
Optimizing Hepatitis B and C Treatment in Resource-Limited Settings
Global Care Cascade for Chronic Hepatitis B and C Virus Infection
Luncheon Symposium
12:50-13:20
State-of-the-Art Lecture I
A 30-Year Journey of Hepatitis C Virus Research: from Discovery to a Cure
13:20-14:20
Keynote Lecture 1. Viral Hepatitis Elimination: Where Do We Stand? It Has Already Reached Halfway by 2030
Notable Milestones Achieved Towards Viral Hepatitis Elimination to Date
Efforts and Strategy to Accelerate Progress Towards Viral Hepatitis Elimination by 2030
It Is Time for a Simplified Approach to Hepatitis B Elimination
Coffee Break
14:40-16:00
PG Course 1. On the Way to HBV Elimination, What Is a Recent Issue?
Strategies to Cure Chronic Hepatitis B: Stopping Oral Antivirals or Interferon Add-on/Switch Therapies
Application of Current Biomarkers to Guide Anti-HBV Treatment
The Optimal Treatment Consideration of Hepatitis B Virus Gray Zone Patients
Risk Factors and Biomarkers for HCC Development after a Cure of Chronic Hepatitis B
Coffee Break
16:20-17:40
PG Course 2. Treatment of Viral Hepatitis, What Progress Is Being Made?
Current Optimal Treatment for Chronic Hepatitis C Virus Infection in Various Clinical Situations
Strategies for the Elimination of Hepatitis C Virus Infection
Current and Emerging Therapeutic Approaches to Hepatitis D Virus Infection
Hepatitis E: Who Should Be Treated?
10:50-11:50
EAST ASIA Joint Symposium: Hepatitis C Virus Elimination
Cost-Effectiveness Hepatitis C Virus Screening and Treatment in South Korea
Clinical Challenges in Hepatitis C Virus Management in Japan
How Would China Achieve WHO's Target of Eliminating the Hepatitis C Virus?
Linkage-to-Care and Follow-Up Strategy for Hepatitis C Virus Infection in Taiwan
Luncheon Symposium 2
Special Symposium
Coffee Break
14:40-16:00
Symposium 1-2. Immunology and Immunotherapy of Viral Hepatitis
Immunological Characteristics of Hepatitis B Virus Infection
Novel Immunological Therapeutics for the Cure of Hepatitis B Virus Infection
Immunological Scars after Hepatitis C Virus Clearance
T-Cell Responses against Hepatitis Viruses
Coffee Break
16:20-17:40
Symposium 1-3. Emerging Antivirals for Hepatitis B Virus Cure
Updates on Drugs for Hepatitis B Virus Entry and/or Post-Entry Inhibition
Updates on Hepatitis B Virus Capsid Assembly Inhibitors
Updates on Drugs Targeting Hepatitis B Virus RNAs: ASOs and siRNA
Updates on cccDNA Disruptors
10:50-11:50
SIG 1.
13:20-14:20
SIG 2. cccDNA and Hepatitis B Virus Integration: Stumbling Blocks for Hepatitis B Virus Cure
Hepatitis B Virus cccDNA: Mechanism of Its Formation and Therapeutic Targets
Hepatitis B Virus Integration and Liver Cancer
Genome Editing for cccDNA and Integrated Hepatitis B Virus
Coffee Break
14:40-16:00
Oral Presentation